ホーム5CV • FRA
add
キュアバック
前日の終値
€3.82
日次変動幅
€3.77 - €3.89
年間変動幅
€2.06 - €4.95
時価総額
8.84億 USD
平均取引高
3.56万
株価収益率
-
配当利回り
-
優先市場
NASDAQ
市場ニュース
財務情報
損益計算書
収益
純利益
(EUR) | 2024年6月info | 前年比変化率 |
---|---|---|
収益 | 1443.60万 | 90.47% |
営業費用 | 4496.60万 | -16.67% |
純利益 | -7254.30万 | -7.61% |
純利益率 | -502.51 | 43.51% |
1 株当たりの収益 | -0.32 | -6.67% |
EBITDA | -6612.70万 | 0.71% |
実効税率 | -1.83% | — |
貸借対照表
総資産
負債総額
(EUR) | 2024年6月info | 前年比変化率 |
---|---|---|
現金および短期投資 | 2.03億 | -62.35% |
総資産 | 5.57億 | -38.09% |
負債総額 | 1.80億 | -28.00% |
純資産 | 3.77億 | — |
発行済み株式 | 2.24億 | — |
帳簿価格 | 2.27 | — |
総資産利益率 | -28.56% | — |
資本利益率 | -39.45% | — |
キャッシュ フロー
現金の純増減額
(EUR) | 2024年6月info | 前年比変化率 |
---|---|---|
純利益 | -7254.30万 | -7.61% |
営業キャッシュ フロー | -8911.30万 | -38.99% |
投資キャッシュ フロー | -748.70万 | 47.30% |
財務キャッシュ フロー | -121.60万 | -1.67% |
現金の純増減額 | -9763.70万 | -22.67% |
フリー キャッシュ フロー | -7498.70万 | -514.20% |
概要
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, a disease caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
設立
2000
ウェブサイト
従業員数
1,086